The Clinical Resource You and Your Patients Need
Endocrine-disrupting chemicals are linked to a growing burden of hormonal, metabolic, and reproductive disorders. The primary research is extensive. The clinical guidance is still remarkably sparse.
The Clinical Portal gives you open-access educational content, validated screening tools, and — for those who want to go deeper — an optional in-depth clinical package. Start with what's free. Go further only if you choose to.
This portal is designed for qualified healthcare professionals. All content is evidence-based and referenced. It is intended to support — not replace — clinical judgement. Nothing on this page constitutes medical advice.
What the evidence says — and what most clinicians were never taught
The science on endocrine-disrupting chemicals is not new, and it is not fringe. Over the past three decades, a substantial body of peer-reviewed research has established that endocrine-disrupting chemicals — synthetic compounds capable of interfering with the body's hormonal systems — are ubiquitous in the modern environment and measurably linked to a wide range of clinical outcomes. The problem is not a lack of evidence. The problem is a lack of translation into everyday care.
Formal Positions
- The Endocrine Society has published two landmark Scientific Statements on endocrine-disrupting chemicals and has repeatedly made clear that the evidence base is sufficient to warrant concern, especially across reproductive, metabolic, thyroid, and developmental outcomes.
- WHO / UNEP formally identified endocrine disruptors as a global threat and called for stronger public-health and regulatory responses.
- NIEHS continues to treat endocrine disruption as a priority research area, with relevance across reproductive, developmental, metabolic, and neurological endpoints.
- European regulatory frameworks now reflect the weight of the evidence through formal criteria and restrictions relevant to endocrine-active chemicals.
The Practical Clinical Problem
- EDC exposure is not a standard component of most medical or allied-health curricula.
- There are no widely adopted mainstream guidelines for assessing or counselling patients on endocrine-disruptor exposure in routine practice.
- Frontline clinicians often recognise the relevance of the issue conceptually, but lack concise tools, structured language, and consultation-ready materials.
- Validated assessment tools exist, but they remain underused and largely unknown in many English-speaking clinical environments.
For clinicians who want the broader systems-level framing before going deeper into chemical families or patient tools, the portal includes a dedicated primer on why EDCs should be understood as a public-health problem — not merely a niche toxicology topic, but a population-scale clinical and policy issue shaped by mixtures, low-dose biology, critical windows, and regulatory lag.
Read the Public Health PrimerEconomic Burden
A 2016 analysis published in The Lancet Diabetes & Endocrinology estimated that endocrine-disruptor-attributable disease costs the European Union approximately €163 billion per year — equivalent to 1.28% of EU GDP. The authors noted that this figure is likely a significant underestimate.
EDCs as a Public Health Problem
Clinical primer on population-level exposure, trend data, economic burden, and clinical relevance.
Read the PrimerHow Exposure Happens
Exposure is not only about what is in a product. It is also about how chemicals reach the body and how long they linger there.
Ingestion
Food, water, packaging, can linings, storage containers, cookware
Eating and drinking create repeated daily contact with relevant materials and residues.
Inhalation
Indoor air, vapors, dust, fragranced products, sprays
Breathing adds ongoing low-dose exposure opportunities inside the home.
Dermal / Mucosal
Personal care, lotions, feminine care, intimate products
Some tissues allow faster or more direct absorption than people often assume.
Dust / Hand-to-Mouth
Furniture dust, floors, electronics, children's items
Especially relevant in household environments and for children's day-to-day contact patterns.
A clinically relevant lens: EDCs, feminine health, and fertility
For many clinicians, one of the clearest and most immediately relevant entry points into endocrine-disruption science is feminine health. The literature does not reduce this issue to a single diagnosis or a single chemical family. Instead, it points to a broad pattern: hormone-active environmental exposures are biologically plausible contributors across multiple estrogen-sensitive, reproductive, and fertility-related endpoints.
Endometriosis and adenomyosis contexts where cumulative hormone disruption and inflammation may be relevant.
Fibroids and other estrogen-responsive tissue outcomes.
PCOS and ovulatory-function questions that intersect with metabolic and endocrine signalling.
Reduced fertility, ovarian reserve concerns, and time-to-pregnancy questions where exposure reduction may be a prudent adjunct.
Pregnancy and preconception windows where low-dose and cumulative exposure deserve especially careful clinical communication.
The goal of this section is not to overstate certainty or suggest a one-cause model of women’s health. The goal is to equip clinicians with a concise, evidence-aware framework for when EDC exposure belongs in the conversation — especially in practices focused on reproductive-age women, fertility, prenatal care, and hormone-sensitive conditions.
The linked subpage is designed as a free clinical primer. It gives enough depth to be genuinely useful while clearly bridging into the fuller paid feminine-health and fertility document inside the Clinical Support Package.
Explore EDCs & Feminine HealthBuilt for clinicians who see the gap
If your patients are asking about hormones, fertility, thyroid health, metabolic function, pregnancy, chronic disease, or everyday environmental exposures, this portal gives you a structured way to respond — without having to build that framework yourself.
GPs & Family Medicine Physicians
First point of contact for patients with hormonal, metabolic, and reproductive concerns. Ideal for initial screening and brief counselling.
Endocrinologists
Managing the disorders most directly linked to endocrine-disruptor exposure. The evidence base in this portal is directly relevant to your patient population.
OBGYNs & Midwives
Prenatal and reproductive-age exposure windows are among the highest-sensitivity periods. The portal is especially useful for this clinical context.
Dietitians & Nutritionists
Dietary exposure is a primary route for many chemical families, and medical nutrition support is a core pillar of the framework.
Paediatricians
Children represent a uniquely vulnerable population. Caregiver counselling tools and priority patient profiles are especially relevant here.
Naturopathic / Integrative Medicine
Your patients are often already asking these questions. The portal provides a more rigorous evidence structure and clinical language.
Occupational Health Physicians
Occupational exposure remains under-addressed. Priority patient profiles include occupationally exposed groups.
Oncology & Cancer Care Teams
Hormone-sensitive cancers and endocrine-disruptor exposure share a growing evidence base. Ongoing exposure reduction can be a relevant counselling adjunct.
Essential foundations — free and open. In-depth clinical framework — available if you need it.
We believe that basic EDC literacy should be accessible to every clinician. The portal is structured in two layers so you can start with what's free, and go further only if your practice demands it.
Open-Access Clinical Education
Substantial, evidence-based resources designed to give any healthcare professional a solid working foundation in endocrine-disruptor science — without cost or commitment.
- Public Health Primer — population-level exposure, trends, and clinical relevance
- Feminine Health Primer — EDCs, reproductive endpoints, and fertility considerations
- Exposure Routes — how patients encounter EDCs in daily life
- Clinical Portal educational content — the full hub you're reading now
- EDES Protocol screening tools — validated, open-source, free to use clinically
Free. No sign-up required. No paywall.
Clinical Support Package
For clinicians who want comprehensive, advanced coverage — from the scientific foundation and screening interpretation to nutrigenomics, laboratory biomarkers, and applied clinical case work.
- Module A — Scientific & mechanistic foundation
- Module B — Screening interpretation & consultation tools
- Module C — Nutrigenomics & detoxification genetics
- Module D — Laboratory biomarkers & clinical correlation
- Module E — Clinical case library & practice implementation
The package is being significantly expanded. Pricing will be confirmed when the new modules are released.
Level 1 is designed to be genuinely useful on its own — not a teaser for a paywall. Many clinicians will find everything they need in the free resources. Level 2 exists for those whose practice calls for a deeper, more structured clinical framework.
Clinical screening tools — open-source
The EDES Protocol (Endocrine Disruptor Exposure Screening) is an open-access family of clinical screening tools designed to help healthcare professionals identify and discuss meaningful endocrine-disruptor exposure with their patients — across all life stages.
Three tools. One framework. The EDES-10 provides a concise 10-domain exposure screen for adults in general clinical practice. The EDES-W is an expanded screen for women of reproductive age, those planning pregnancy, or in early pregnancy — addressing hormonal, fertility, and fetal programming considerations. The EDES-P is a life-stage stratified screen covering infancy, childhood, and adolescence, designed for paediatric clinicians, family physicians, and allied health professionals.
All tools are published under a Creative Commons licence (CC BY-NC-SA 4.0) and may be used freely in clinical, educational, and public-health settings.
Visit the EDES ProtocolWhat you will find
- EDES-10 — General adult EDC exposure screen
- EDES-W — Women's & preconception screen
- EDES-P — Pediatric screen (infancy, childhood, adolescence)
- Scoring guides & interpretation notes
- Supporting clinical documentation
Designed for real clinical environments
Concise and consultation-ready
Every document is structured for use in practice, not academic study.
Referenced but not overwhelming
All content is evidence-based and cited, without requiring the user to read the primary literature first.
Patient-ready where it counts
The handouts and script tools are designed to be used directly with patients, without editing.
From evidence to practice — in three steps
The Clinical Portal is structured around the three things a clinician actually needs: to understand the problem deeply, to assess which patients are most affected, and to communicate effectively without adding time to an already pressured consultation.
Understand
Build a rigorous, evidence-based clinical understanding of the endocrine-disruptor problem — from mechanisms of action to chemical families, from public-health framing to female health implications. The educational layer is organised for clinical use, not academic wandering.
Assess
Identify which patients are most likely to benefit from exposure-reduction guidance. Priority patient profiles, risk-factor checklists, and structured clinical reasoning help you decide who needs counselling — and when. For validated clinical screening tools, see the EDES Protocol.
Counsel & Support
Communicate clearly and confidently using ready-made scripts, a patient-facing language guide, and printer-ready handouts. Everything is designed to reduce prep time and increase clinical usability.
Five modules. One clinical framework.
The Clinical Support Package is being significantly expanded. Following the launch of the EDES screening tools as open-access resources, the paid package has been restructured to go deeper — providing advanced interpretation, genomic, and applied clinical layers that free tools cannot.
Currently in development
New modules are being built and will be released progressively. Existing module content remains available. Pricing will be confirmed when the expanded package is complete.
Module A — Understand
Scientific & Mechanistic Foundation
The evidence backbone of the package. EDC evidence matrix across 8–9 chemical families, mechanism maps, non-monotonic dose-response science, absorption routes, medical nutrition summaries, and dedicated primers on female and male reproductive health.
Module B — Assess & Communicate
Screening Interpretation & Consultation Tools
The professional interpretation layer that sits above the free EDES screening tools. Score interpretation guides, follow-up monitoring frameworks, rapid consultation scripts, shared decision-making tools, and communication templates for genomic and laboratory findings.
Module C — Genomics
Nutrigenomics & Detoxification Genetics
Why genetic variants in Phase I/II detoxification, methylation, and hormone metabolism determine individual EDC burden — and the targeted nutritional strategies to address each. Includes gene–nutrient bypass matrices and patient communication guides.
Module D — Interpret
Laboratory Biomarkers & Clinical Correlation
The laboratory layer connecting exposure screening and genetic profiling to measurable clinical endpoints. Biomarker selection, hormonal and metabolic markers in the EDC context, oxidative stress indicators, and a structured ordering framework.
Module E — Apply
Clinical Case Library & Practice Implementation
Applied clinical learning through composite case scenarios, CPD scaffolding, and a complete practice implementation kit — from clinic onboarding guides to referral letter templates and EMR documentation prompts.
What the evidence says
The Endocrine Society (2015)
“Accumulating evidence supports the conclusion that endocrine-disrupting chemicals affect male and female reproduction, thyroid function, metabolism and obesity, insulin and glucose homeostasis, and neuroendocrinology.”
WHO / UNEP (2013)
“Endocrine disruptors represent a global threat and the scientific evidence is strong enough to warrant action.”
NIEHS
“Endocrine-disrupting chemicals remain among the Institute’s priority research areas across reproductive, developmental, metabolic, and neurological outcomes.”
Trasande et al., The Lancet (2016)
“EDC-attributable disease costs in the EU estimated at approximately €163 billion annually.”
Vandenberg et al., Endocrine Reviews (2012)
“Landmark work on non-monotonic dose-response relationships, demonstrating biological activity at trace concentrations below conventional assumptions.”
The Clinical Portal draws on a large peer-reviewed body of literature, including primary research, systematic reviews, and formal institutional statements. A full reference list is available within the package.
The expanded Clinical Support Package is coming soon
Five modules spanning scientific foundations, clinical screening, nutrigenomics, laboratory interpretation, and applied case work — structured for real clinical environments and designed for professionals who want to go deep.
New modules are currently in development and will be released progressively. Pricing will be confirmed when the expanded package is ready.
In the meantime, all Level 1 resources — including clinical primers, the full portal educational content, and the EDES Protocol screening tools — remain free and fully available.
Endocrine Resilience clinical materials are designed to support healthcare professionals in patient education and counselling. They do not constitute medical advice and are not a substitute for clinical training or professional judgement. All content is evidence-based and referenced. © Endocrine Resilience 2025.